UNSPSC 51343801: Abacavir/lamivudine

This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class AM800. This VA Drug Class (AM800) classifies this compound as belonging to the group ANTIVIRALS.

The first component of this combination drug is a reverse transcriptase inhibitor with the molecular formula C14H18N6O, a preparation that US FDA recognizes as an active ingredient or moiety under Unique Ingredient Identifier WR2TIP26VS, chemically known as 2-cyclopentene-1-methanol, 4-(2-amino-6-(cyclopropylamino)-9h-purin-9-yl)-, (1s-cis)- but more generally known as abacavir, which bears U.S. National Institutes of Health Compound Identifier 65140. Abacavir most often appears in forms succinate and sulfate, and is sometimes combined with lamivudine and zidovudine.

UNSPSC 51343801 Abacavir/lamivudine is a Commodity code that nominally identifies a specific antiretroviral pharmaceutical product, but recent state and local procurement activity under this code shows limited direct purchasing of the named drug. The code appears in state health department and county procurement records, though the actual solicitations tagged to it diverge significantly from the code's stated scope. State and local governments use this code tier to flag pharmaceutical acquisitions through cooperative purchasing agreements and piggyback contracts with established pharmaceutical vendors, typically via consortia such as MMCAP. When activity does align with the code's intent, purchasing focuses on bulk pharmaceutical inventory for public health stockpiling, emergency preparedness, and disease prevention programs. Issuing bodies include state departments of public health, county health departments, and special-purpose health authorities conducting competitive bidding through IFB and RFQ processes.

Recent opportunities demonstrate geographic dispersion across at least Florida and Illinois. The Illinois Department of Public Health awarded a $2,999,999.11 piggyback pharmaceutical warehouse contract to Chartwell Rx LLC on August 28, 2026 (IFB 26482DPHPREPDB53392) for Doxycycline Hyclate 100mg and Ciprofloxacin Hydrochloride 500mg tablets with a 12-month initial term and two optional renewal years. Seminole County, Florida issued an IFB (IFB60459723LAS) with a July 26, 2023 response deadline for 1,900 units of Naloxone and 800 Safe Drug Deactivation Systems annually with quarterly deliveries. Both opportunities required electronic bid submission, vendor insurance compliance, and E-Verify authorization. Notably, the Illinois award and Seminole County solicitation both diverge substantially from abacavir/lamivudine scope, suggesting the code is either inconsistently applied in state procurement systems or the recent activity sample reflects tagging mismatches rather than true demand for this specific antiretroviral product line.